logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics teams up with Croda for first commercial deal

The company will be working with Croda unit Sederma, which will design and manufacture “new unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market”

SkinBioTherapeutics teams up with Croda unit as it lands its first commercial deal

SkinBioTherapeutics PLC (LON:SBTX) has inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA).

It secures the AIM-listed life sciences group its first deal and also provides third-party validation of its technology.

Full financial terms were not revealed; however, SkinBioTherapeutics will receive “tiered royalties” on sales of any products that result from the partnership.

The company will be working with Croda unit Sederma, which will design and manufacture “new unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market”.

“This deal offers the potential for SkinBiotix to be incorporated into some of the world's biggest cosmetics brands, which was always the vision that we had for the technology,” said Dr Cath O’Neill, SkinBioTherapeutics’ chief scientific officer.

The agreement leaves the company free to pursue commercial applications in other sectors.

Sederma managing director Arnaud Fournial said his group had been drawn to the SkinBiotix platform because of its “solid scientific foundation”.

“We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market,” he explained.

Talking to Proactive Stuart Ashman, SkinBioTherapeutics’s chief executive, said that through the deal it is giving Sederma access to its science.

In return, it gets access to the Croda’s subsidiary huge base of cosmetic customers and a validated source of supply that it can use in other applications.

 “It is our very first commercial deal. It validates the science and gives us a solid industry partner with 12,000 customers and a very credible supply chain.”

Skinbiotex uses lysates (extracts) of probiotic bacteria and will be offered as an active ingredient in barrier protection and anti-ageing cosmetics.

Products such as mouthwashes or toothpaste and the other applications such as med-tech, pharma and hospital-acquired infections are not included.

Croda is an excellent partner, Ashman added.

“Going with one of the large brands would have limited us to a single company, this way we get to cover the entire market and every customer of Sederma and Croda now gets exposure to Skinbiotix.”

 

-- adds extra comment --

Quick facts: SkinBioTherapeutics PLC

Price: 14.25 GBX

AIM:SBTX
Market: AIM
Market Cap: £18.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA). Ashman says it's a significant first...

3 weeks, 4 days ago

RNS

Notice of AGM

2 weeks, 5 days ago

Final Results

2 weeks, 5 days ago

Commercial Agreement

3 weeks, 4 days ago

2 min read